23. Patient profiling in HFrEF for tailoring medical therapy:
Strategy in patients with elevated heart rate
24. Patient Phenotype Profiling in HF with Preserved Ejection Fraction to Guide Therapeutic
Decision Making A Scientific Statement of the HFA, ERHA, and ESH. (EJC-HF May 19,2023)
25. Modern HF Care based for Each of the 4 LVEF –Based Groups
31. SGLT2i in Heart Failure - Talk of the town
across all academic forums
32. • Single dose, no titration
• Can be started in hospital or in the community
• Benefit within <28 days
• Outstanding tolerability
• Negligible effect on blood pressure
• Preserves rather than worsens renal function
• Reduces risk of hyperkalemia with MRAs (another concept: agents started earlier can enhance
the safety of agents started later)
• Expanding indications, expanding benefits!!
SGLT2i (Dapagliflozin) – in 2023!
Editor's Notes
Graphic depiction of course of heart failure admission, showing the degree of focus on clinical decompensation (red), discharge coordination (blue), ongoing coordination of outpatient care (light blue), and optimization of guideline-directed medical therapy (green), with ongoing assessment of the clinical course (circle with arrows), and key time points for review and revision of the long-term disease trajectory for the HF journey (compass signs).
